Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Livaro VA
- Development stage
- Unknown
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Livaro VA (JW0102) is a fixed-dose combination (FDC) therapy developed by JW Pharmaceutical for the treatment of patients with both hypertension and dyslipidemia. It integrates three active ingredients: amlodipine, a dihydropyridine calcium channel blocker (CCB); valsartan, an angiotensin II receptor blocker (ARB); and pitavastatin, an HMG-CoA reductase inhibitor (statin). This triple combination is designed to simplify treatment regimens and improve medication adherence in patients requiring multi-drug therapy for cardiovascular risk management. By simultaneously targeting peripheral vascular resistance, the renin-angiotensin-aldosterone system, and hepatic cholesterol synthesis, Livaro VA provides a comprehensive approach to reducing cardiovascular risk in comorbid patients.
- Brand names
- Livaro VA
- Other names
- amlodipine + valsartan + pitavastatin
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on Livaro VA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Livaro VA.